NCT07235514 Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2
| NCT ID | NCT07235514 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 958 participants |
| Start Date | 2026-03-24 |
| Primary Completion | 2029-06-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 958 participants in total. It began in 2026-03-24 with a primary completion date of 2029-06-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn what is the best anesthetic management in participants with severe stroke that require a medical intervention called mechanical thrombectomy (MT) done to open the occluded brain vessel. The main question it aims to answer is: • Is general anesthesia (GA) better than procedural sedation (PS) for improving functional performance and decrease dependance in daily life 3 months after stroke? GA (a non-arousable state induced by anesthetic medications that require respiratory assistance) or PS (a state of reduced arousal induced by lesser dose of anesthetic medications that do not require respiratory assistance) are both used for MT. GA enables strict immobility that could facilitate the conduct of MT but lessen blood pressure and blood flow in the brain. PS provides less drop in blood pressure but MT could be more difficult due to possible movement and breathing may be decreased. Researchers will compare GA with PS to see which one is better for MT success and for the functional consequences of stroke. Participants will be treated with GA or PS for the intervention of MT and will be followed by researchers during their hospital stay and asked by a telephone interview how is their functional status 3 months after stroke.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Acute ischemic stroke with an occlusion of the intracranial internal carotid artery and/or the proximal middle cerebral artery (M1-M2) with or without association of extracranial occlusion of the cervical internal carotid artery (tandem lesion) * Eligible for mechanical thrombectomy according to international guidelines * Informed and signed consent of patient, or if he is unable to consent the consent of patient's relative or emergency procedure in the absence of relative * National health insurance Exclusion Criteria: * Coma or altered vigilance defined as a score ≥ 2 on the level of consciousness 1A subscale of the NIHSS * Premorbid disability defined as a mRS \> 2 * Posterior circulation stroke * Associated cerebral hemorrhage * Stroke complicating another acute illness or postoperative stroke * Emesis at arrival in angiosuite * Allergy to anesthetic medication * Pregnant or breast-feeding women * Adult under the protection of the law
Contact & Investigator
Russell CHABANNE
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT07235514 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07235514 currently recruiting?
Yes, NCT07235514 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT07235514 trial being conducted?
This trial is being conducted at Angers, France, Brest, France, Clermont-Ferrand, France, Lille, France and 11 additional locations.
Who is sponsoring the NCT07235514 clinical trial?
NCT07235514 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Russell CHABANNE at University Hospital, Clermont-Ferrand. The trial plans to enroll 958 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.